Avid Bioservices, Inc.
CDMOHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $139.9M | $149.3M | $119.6M | $95.9M | $59.7M | $53.6M |
| Operating income | −$18.7M | $3.6M | $15.4M | $12.2M | −$10.9M | −$5.6M |
| Net income | −$140.8M | $259,000 | $127.7M | $11.2M | −$10.5M | −$4.2M |
| Total assets | $336.6M | $451.6M | $429.8M | $265.5M | $107.6M | $78.4M |
| Total liabilities | $275.7M | $262.4M | $255.3M | $187.8M | $65.7M | $25.3M |
| Equity | $60.9M | $189.2M | $174.5M | $77.7M | $41.9M | $53.1M |
| EPS (diluted) | $-2.23 | $0.00 | $1.84 | $0.06 | $-0.27 | $-0.16 |
| Shares out. | 63.6M | 62.7M | 61.8M | 61.1M | 56.5M | 56.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −13.3%
- Net margin
- −100.6%
- Return on equity
- −231.2%
- Return on assets
- −41.8%
- Return on capital (ROCE)
- −7.0%
- Liabilities / assets
- 81.9%
- Debt / equity
- 4.53×
- Book value / share
- $0.96
- Revenue growth (YoY)
- −6.3%
- Net income growth (YoY)
- −54444.8%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -5.03distress
- Accruals / assets
- −45.1%clean
- Beneish M-Score
- -3.49normal
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 4 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue declined year-over-year
- High leverage (liabilities > 70% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Mar 12, 2024
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Glazer Capital, LlcPassive (13G)May 15, 2025
- Point72 Asset Management, L.P.Passive (13G)Feb 14, 2025
- Altravue Capital, LlcPassive (13G)Jan 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Ziebell Mark ROfficer — V. P., General Counsel | Feb 5, 2025 | D | 66,799 | — |
| Thoma JeanneDirector | Feb 5, 2025 | D | 45,611 | — |
| Sargen GregoryDirector | Feb 5, 2025 | D | 36,368 | — |
| Richieri Richard A.Officer — Chief Operations Officer | Feb 5, 2025 | D | 49,535 | — |
| Mackey Catherine JDirector | Feb 5, 2025 | D | 43,379 | — |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventFeb 5, 2025
- Shareholder vote · Regulation FD disclosureJan 30, 2025
- Results of operationsDec 10, 2024
- Entered a material agreement · Regulation FD disclosureNov 7, 2024
- Director / officer change · Shareholder voteOct 17, 2024
- Results of operations · Regulation FD disclosureSep 9, 2024
- Director / officer changeAug 29, 2024
- Results of operations · Regulation FD disclosureJul 2, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.